title: Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.
abstract: BACKGROUND
  Adalimumab is used in an attempt to maintain remission for Ulcerative colitis. This study was to evaluate the efficacy and adverse events of adalimumab compared with placebo in inducing remission of Ulcerative colitis.
  
  
  METHODS
  MEDLINE, EMBASE, the Cochrane Controlled Trials Register, OVID, BIOSIS, CNKI, and Google were searched. All randomized trials comparing adalimumab with placebo in inducing remission of moderate-to-severe ulcerative colitis were included.
  
  
  RESULTS
  Two randomized controlled trials with a total of 754 participants met the inclusion criteria. The pooled risk ratio (RR) of clinical remission was 1.85 (95% confidence interval (CI) 1.26 to 2.72) following adalimumab treatment. RR of clinical response was 1.40 (95% CI 1.19 to 1.65) while that of mucosal healing was 1.23 (95% CI 1.03 to 1.47). RR of any adverse events was 1.00 (95% CI 0.93 to 1.09).
  
  
  CONCLUSIONS
  Compared with placebo, administration of adalimumab may increase the proportion of patients with moderate-to-severe ulcerative colitis attaining clinical remission, clinical response and mucosal healing. Adalimumab is also tolerated well in these patients.
authors.affiliation: Department of Psychiatry, Affiliated Hospital of Guangdong Medical College Zhanjiang, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Department of Psychiatry, Affiliated Hospital of Guangdong Medical College Zhanjiang, China.
authors.forename: Xiao-Qing
authors.initials: XQ
authors.lastname: Ye
authors.affiliation: Department of Pharmacology, Guangdong Medical College Dongguan, China.
authors.forename: Yu-Zhen
authors.initials: YZ
authors.lastname: Zhu
authors.affiliation: Department of Neurology, Affiliated Hospital of Guangdong Medical College Zhanjiang, China.
authors.forename: Zhou
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Traditional Chinese Medicine, The Second Clinical Medical School, Guangdong Medical College Dongguan, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zou
authors.affiliation: Department of Pharmacology, Guangdong Medical College Dongguan, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Deng
authors.affiliation: Department of Pharmacology, Guangdong Medical College Dongguan, China.
authors.forename: Can-Can
authors.initials: CC
authors.lastname: Guo
authors.affiliation: Department of Surgery, University of Minnesota Minneapolis, USA.
authors.forename: Sushil Kumar
authors.initials: SK
authors.lastname: Garg
authors.affiliation: Institute of Traditional Chinese Medicine, Guangdong Medical College Zhanjiang, China.
authors.forename: Jin-Shan
authors.initials: JS
authors.lastname: Feng
keywords: Adalimumab; efficacy; meta-analysis; safety; ulcerative colitis